Free Trial

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

Nektar Therapeutics logo
$84.91 +0.75 (+0.89%)
As of 10:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Nektar Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
1
Buy
9

Based on 11 Wall Street analysts who have issued ratings for Nektar Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a sell rating, 1 has given a hold rating, and 9 have given a buy rating for NKTR.

Consensus Price Target

$140.63
65.62% Upside
According to the 11 analysts' twelve-month price targets for Nektar Therapeutics, the average price target is $140.63. The highest price target for NKTR is $185.00, while the lowest price target for NKTR is $95.00. The average price target represents a forecasted upside of 65.62% from the current price of $84.91.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NKTR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Nektar Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NKTR Analyst Ratings Over Time

TypeCurrent Forecast
5/6/25 to 5/6/26
1 Month Ago
4/6/25 to 4/6/26
3 Months Ago
2/5/25 to 2/5/26
1 Year Ago
5/6/24 to 5/6/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$140.63$128.13$110.86$67.50
Forecasted Upside65.62% Upside71.47% Upside215.65% Upside600.93% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyBuy

NKTR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NKTR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nektar Therapeutics Stock vs. The Competition

TypeNektar TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.73
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside65.12% Upside938.18% Upside14.81% Upside
News Sentiment Rating
Neutral News

See Recent NKTR News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
4/22/2026 Reiterated RatingBuy
4/21/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
Boost TargetBuy$123.00 ➝ $151.00+53.59%
4/21/2026
Wedbush logo
Wedbush
5 of 5 stars
Martin Fan
Martin Fan
Not Rated
Boost TargetNeutral$70.00 ➝ $95.00-5.33%
4/20/2026Boost TargetBuy$151.00 ➝ $178.00+69.18%
4/20/2026Boost TargetBuy$165.00 ➝ $185.00+75.83%
3/17/2026Initiated CoverageBuy
3/13/2026Reiterated RatingOutperform$140.00+91.79%
2/23/2026Reiterated RatingBuy$105.00 ➝ $150.00+108.72%
2/10/2026 UpgradeMarket PerformOutperform
1/26/2026Reiterated RatingOverweight$105.00+187.95%
12/29/2025 Reiterated RatingSell (E+)
6/28/2024 Initiated CoverageBuy$30.00+75.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:22 AM ET.


NKTR Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Nektar Therapeutics is $140.63, with a high forecast of $185.00 and a low forecast of $95.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There is currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NKTR shares.

According to analysts, Nektar Therapeutics's stock has a predicted upside of 65.62% based on their 12-month stock forecasts.

Over the previous 90 days, Nektar Therapeutics's stock had 1 upgrade by analysts.

Nektar Therapeutics has been rated by research analysts at B. Riley Financial, BTIG Research, Citigroup, HC Wainwright, Jefferies Financial Group, Oppenheimer, TD Cowen, Wedbush, and William Blair in the past 90 days.

Analysts like Nektar Therapeutics more than other "medical" companies. The consensus rating for Nektar Therapeutics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how NKTR compares to other companies.


This page (NASDAQ:NKTR) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners